{
  "company": {
    "name": "Cyana Therapeutics",
    "website": "https://cyanatx.com/",
    "record": "https://startuphistory.org/c/cyanatx.com"
  },
  "status": null,
  "history_since": "2026-07-12T11:26:58.000Z",
  "baseline": {
    "snapshot_id": "1beab5619edd4329fce515587bc7752d48b033fb486e0fd58d9813d9d0baa2bc",
    "observed_at": "2026-07-12T11:26:58.000Z",
    "headline": "Precision Immuno-Oncology",
    "description": "Cyana Therapeutics is a precision immuno-oncology company developing CY-3132, a small molecule ENPP1 inhibitor for the treatment of solid tumors. IND open, Phase 1 clinical trial planned for 2026.",
    "evidence": "https://web.archive.org/web/20260712112658/https://cyanatx.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T13:09:54.772Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2026-11-05T13:09:54.772Z",
      "variants": [
        {
          "headline": "Precision Immuno-Oncology",
          "subhead": "Cyana Therapeutics is a precision immuno-oncology company developing CY-3132, a small molecule ENPP1 inhibitor for the treatment of solid tumors. IND open, Phase 1 clinical trial planned for 2026.",
          "observed_at": "2026-07-12T11:26:58.000Z",
          "evidence": "https://web.archive.org/web/20260712112658/https://cyanatx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Precision Immuno-Oncology",
          "subhead": "Cyana Therapeutics is a precision immuno-oncology company developing CY-3132, a small molecule ENPP1 inhibitor for the treatment of solid tumors. IND open, Phase 1 clinical trial planned for 2026.",
          "observed_at": "2026-11-05T13:09:54.772Z",
          "evidence": "https://cyanatx.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Precision Immuno-Oncology",
      "subhead": "Cyana Therapeutics is a precision immuno-oncology company developing CY-3132, a small molecule ENPP1 inhibitor for the treatment of solid tumors. IND open, Phase 1 clinical trial planned for 2026.",
      "from": "2026-07-12T11:26:58.000Z",
      "to": "2026-11-05T13:09:54.772Z",
      "captures": 2,
      "evidence": "https://cyanatx.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2026-07-12T11:26:58.000Z",
          "to": "2026-11-05T13:09:54.772Z"
        }
      },
      "current": true
    }
  ],
  "changes": [],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Cyana Therapeutics” company record, https://startuphistory.org/c/cyanatx.com"
}